BioScrip, Inc., provider of comprehensive pharmaceutical care solutions, has partnered with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of life. The company offers services in four core areas; specialty medications delivered via mail, pharmacy benefit management, community pharmacies and infusion services.
The company’s pharmacy benefit management programs include customized benefit plan design, pharmacy network management and sophisticated reporting capabilities that deliver improved clinical and economic outcomes. BioScrip’s specialty medication distribution capability includes condition specific clinical management programs tailored to improve the care of individuals with complex health conditions.
BioScrip recently closed the acquisition of CHS and has made significant progress with integration efforts. The company is on target to reach cost synergy goals and has identified additional cost of goods savings. According to CEO Richard H. Friedman, the company is already seeing tangible results from cross-selling efforts and believes that the combined platform positions BioScrip to be a leading national, specialty pharmacy provider.
Four analysts cover the company with two issuing “Strong Buy” ratings and the remainder recommending the stock as a “Buy”. The stock currently trades at a trailing P/E ratio of 4.65 and P/S of 0.21, both of which are considered extremely undervalued within the healthcare industry. With a cash position of $37.2 million, BioScrip has total assets of $714.6 million and total liabilities of $458.3 million.
Let us hear your thoughts below: